JDRF Celebrates Progress in Type 1 Diabetes Research at the American Diabetes Association 82nd Scientific Sessions
New York, June 9, 2022— JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, celebrates innovation, progression, and acceleration of research to treat, prevent and cure T1D and its complications at the American Diabetes Association’s (ADA) 82nd Scientific Sessions. Taking place at the Ernest N. Morial Convention Center in New Orleans, JDRF-funded researchers from across the globe participated in curated presentation sessions to share research updates showcasing breakthroughs and therapies.
“We are excited to be returning in person and virtually to the Scientific Sessions and congratulate ADA on another successful event,” said Sanjoy Dutta, Ph.D., JDRF Chief Scientific Officer. “As one of the premier gatherings of leaders from the diabetes ecosystem, the Scientific Sessions represent and showcase the best of the best within our industry from research to technology and more.”
This year, researchers with a past or present connection to JDRF presented more than 120 studies encompassing breakthrough clinical trials and research studies paving the way to novel and emerging treatments for T1D.
Key highlights from the weekend included:
- Renowned international researcher Chantal Mathieu, M.D., Ph.D., and colleagues discuss early T1D diagnosis and management.
- Vertex Pharmaceuticals shares positive results from the three patients enrolled in the phase I/II clinical trial for VX-880.
- Progression in therapies to delay and prevent T1D spotlighted in presentations from researchers, including Kevan Herold, M.D., Laura Jacobsen, M.D., Alice Long, Ph.D., Audrey Parent, Ph.D., and Matthias von Herrath, M.D.
- Abbott announces the development of a single device that will combine a continuous glucose monitor (CGM) and continuous ketone monitor (CKM).
- Shivani Agarwal, M.D., M.P.H discussed novel diabetes prevention and treatment approaches for underserved and diverse populations and settings.
“For more than 50 years, JDRF’s leadership has helped to propel novel therapies and technological advances into the market for individuals impacted by T1D,” says Dutta. “The ADA Scientific Sessions serve as a pivotal benchmark in the continued progression of the evolving research landscape for some of the world’s brilliant diabetes researchers to share and be inspired.”
For more information on JDRF-funded presentations please visit, https://www.jdrf.org/blog/2022/06/01/jdrf-heads-in-person-adas-82nd-scientific-sessions/
JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).